Bridge, KI, Bollen, L, Zhong, J et al. (7 more authors) (2017) Thrombin-Activatable Fibrinolysis Inhibitor in Human Abdominal Aortic Aneurysm Disease. Journal of Thrombosis and Haemostasis, 15 (11). pp. 2218-2225. ISSN 1538-7933
Abstract
Background: Intra-luminal thrombosis is a key factor in Abdominal Aortic Aneurysms (AAA) growth. Patients with AAA form dense clots that are resistant to fibrinolysis. Thrombin-activatable fibrinolysis inhibitor (TAFI) has been shown to influence AAA development in murine models. Objective: The aim of this study is to characterise the role of TAFI in human AAA. Methods: Plasma levels of TAFI, TAFI activation peptide (TAFI-AP), activated/inactivated TAFI (TAFIa/ai) and plasmin-α2-antiplasmin complex were measured by ELISAs in patients with AAA (n=202) and controls (n=188). Results: TAFIa/ai and TAFI-AP levels were higher in patients than controls (median (IQR): 20.3 (14.6-32.8) vs. 14.2 (11.2-19.3) and 355.0 (232.4-528.1) vs. 248.6 (197.1-328.1) ng/ml). TAFIa/ai was positively correlated with TAFI-AP (r=0.164). Intact TAFI levels were not different between patients and controls (13.4 (11.2-16.1) vs. 12.8 (10.6-15.4) μg/ml). Plasmin-α2-antiplasmin was higher in AAA patients than controls (690.0 (489.1-924.3) vs. 480.7 (392.6-555.3) ng/ml). Conclusions: The increase in TAFIa/ai and TAFI-AP suggest an increased TAFI activation in patients with AAA. Prospective studies are required to further elucidate the role of TAFI and fibrinolysis in AAA pathogenesis.
Metadata
Item Type: | Article |
---|---|
Authors/Creators: |
|
Copyright, Publisher and Additional Information: | © 2017 International Society on Thrombosis and Haemostasis. This is the peer reviewed version of the following article: Bridge KI, Bollen L, Zhong J, Hesketh M, Macrae FL, Johnson A, Philippou H, Scott DJ, Gils A, Ariёns RAS (2017) Thrombin-Activatable Fibrinolysis Inhibitor in Human Abdominal Aortic Aneurysm Disease. Journal of Thrombosis and Haemostasis; 15: 2218–2225, which has been published in final form at https://doi.org/10.1111/jth.13804. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving. Uploaded in accordance with the publisher's self-archiving policy. |
Keywords: | Abdominal aortic aneurysm; Carboxypeptidase B2; Fibrinolysis; Thrombin-activatable fibrinolysis inhibitor; Thrombosis |
Dates: |
|
Institution: | The University of Leeds |
Academic Units: | The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Genetics, Health and Therapeutics (LIGHT) > Academic Unit of Cardiovascular Medicine (Leeds) |
Funding Information: | Funder Grant number Circulation Foundation NOT GIVEN British Heart Foundation FS/12/26/29395 |
Depositing User: | Symplectic Publications |
Date Deposited: | 22 Aug 2017 13:01 |
Last Modified: | 22 Aug 2018 00:38 |
Status: | Published |
Publisher: | Wiley |
Identification Number: | 10.1111/jth.13804 |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:120480 |